Application of compound laetispicine in the process for preparing pharmaceutical composition

A technology of phytocarpine and its compound, which is applied in the field of traditional Chinese medicine pharmacy, and can solve problems such as unsatisfactory clinical treatment

Inactive Publication Date: 2005-03-16
FUDAN UNIV
View PDF0 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, various related chemical drugs still cannot meet the growing needs of clinical treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compound laetispicine in the process for preparing pharmaceutical composition
  • Application of compound laetispicine in the process for preparing pharmaceutical composition
  • Application of compound laetispicine in the process for preparing pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1 Extraction and separation of phytocarpine

[0016] After pulverizing 1000g of raw medicinal materials, add 6 times the amount of 95% industrial alcohol to heat and reflux for 2 hours, filter after cooling, add 4 times the amount of 95% industrial alcohol to the residue for secondary reflux, cool and filter, and combine the filtrates twice. Concentrate to dryness under reduced pressure to obtain 50 g of ethanol extract. Add an appropriate amount of water to the ethanol extract, use five times the amount of petroleum ether, benzene, chloroform, and ethyl acetate to carry out 1:1 extraction, a small amount for multiple times, heat to reflux, cool and separate, combine the organic phases, and concentrate under reduced pressure. 0.5 g of petroleum ether extract, 8 g of benzene extract, 6 g of chloroform extract, and 10 g of ethyl acetate extract were obtained. 10 g of ethyl acetate extract was subjected to silica gel column chromatography, and gradient elution was...

Embodiment 2

[0017] Example 2 Isotope-labeled Central Nervous System Monoamine Transmitter Reuptake Inhibition Test

[0018] 150-250g Sprague-Dawley male rats were taken, the neck was broken, the brain was taken out, and the brain area was stripped. The hypothalamus was used for 5-HT and NE reuptake inhibition experiments, and the striatum was used for DA reuptake inhibition experiments. Weighed, Add 25mL / g ice-cold 0.32M sucrose solution, and homogenize in an ice bath. The homogenate was refrigerated and centrifuged at 1000 rpm for 10 min, the precipitate was discarded, and the supernatant was taken, and refrigerated and centrifuged at 10000-17000 rpm for 20 min. The precipitate is the synaptosome. Suspend with the aforementioned 0.32M sucrose solution at a ratio of 10mL / g (according to the wet weight of brain tissue). Determine protein content. spare.

[0019] h 3 The labeled monoamine transmitter was diluted 200 times with freshly prepared Krebs solution. Take 800μL+20μL drug (or ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the use of compound Laetispicine in the process for preparing pharmaceutical compositions for suppressing central nerve system monoamine transmitter reuptake related diseases, wherein the compound Laetispicine can be used as raw material for preparing pharmaceutical compositions for inhibiting central nerve system monoamine transmitter reuptake related diseases.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicine pharmacy, and relates to the application of an amide compound kopinusin isolated from the plant Kelpia chinensis in the preparation of a pharmaceutical composition. In particular, it relates to the use of kopinusin in the preparation of a pharmaceutical composition for inhibiting central nervous system monoamine transmitter reuptake-related diseases. Background technique [0002] With the continuous improvement of people's quality of life and health, nervous, mental, cardiovascular and endocrine system diseases have become frequent diseases that endanger human health in the world today, and have brought a heavy burden to human society. 5-hydroxytryptamine (5-HT), dopamine (DA) and norepinephrine (NE) are the most important monoamine transmitters in the central nervous system. Their content in the brain controls human emotions and emotions, regulates cardiovascular and endocrine functio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/357A61K31/5585A61P15/08A61P25/14A61P25/16A61P25/18A61P25/22A61P25/24
CPCA61K31/5585A61K31/357A61P15/08A61P25/00A61P25/04A61P25/14A61P25/16A61P25/18A61P25/22A61P25/24A61P25/28
Inventor 潘胜利钱伏刚王峻孙凤艳解静邵衣慈
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap